Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChen LiangDYDonglin YangMHMingzhe Han

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows triplet therapy improves outcomes in FLT3-ITD mutated AML patients, suggesting potential for better transplant success.

Key Points

  • Evaluate efficacy and safety of triplet therapy with venetoclax, azacitidine, and gilteritinib in high-risk AML patients.
  • Retrospective cohort analysis of 48 FLT3-ITD mutated AML patients
  • Patients received triplet therapy as a bridge to allo-HSCT
  • Bone marrow aspirates and cytogenetic characteristics were analyzed
  • 39 patients (81.3%) achieved complete remission or complete remission with incomplete blood count recovery (CR/CRi)
  • 1-year overall survival rate was 83.3% and relapse-free survival rate was 75.0%
  • 18.8% of patients experienced disease relapse

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e535https://doi.org/10.1182/blood-2025-2519
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia2025 · 1 citations
  2. 2Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML2026 · 1 citations
  3. 3Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome2025 · 2 citations
  4. 4Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  5. 5Gilteritinib with or without venetoclax for relapsed/refractory <i>FLT3</i>‐mutated acute myeloid leukaemia2024 · 5 citations